EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Development of a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders: Study protocol for the naltrexone neuroimaging randomized controlled trial (NN-RCT)

Stephani L Stancil, Mariah E Brewe, John Tumberger, Michael Bartkoski, Anna Burns, Hung-Wen Yeh, Morgan G Brucks, James Bartolotti, Michaela Voss, Jeffrey R Strawn, Susan Abdel-Rahman, Ann Davis und 2 weitere

Contemporary Clinical Trials · 2025

DOI: 10.1016/j.cct.2025.107874 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2025. Verfasst von Stephani L Stancil und 13 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Adolescent Medicine and Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, United States; Depar…. Hauptthemen laut MEDLINE: Feeding and Eating Disorders, Naltrexone, Narcotic Antagonists. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NCATS NIH HHS, National Institute of Mental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eating disorders (ED) affect 5 % of youth, are associated with reward system alterations, and lead to substantial morbidity. Naltrexone, an opioid antagonist, is used to treat ED behaviors such as binge eating and purging. However, not all patients respond, and the optimal dose is unknown. Neuroimaging may serve as a tool to detect drug response in the brain, acting as a pharmacodynamic biomarker to support therapeutic optimization. Currently, no pharmacodynamic biomarkers for psychopharmacology exist. Building on pilot work, we present the protocol for a randomized controlled trial to validate neuroimaging as a pharmacodynamic biomarker of opioid antagonism in adolescents with ED. Youth aged 13-21 years with binge/purge ED are randomized to receive a single dose of oral naltrexone and placebo in a double-blind using a crossover design with an interdose interval ≥ 2 weeks. Task-based functional neuroimaging detects reward pathway modulation 2 h post-dose. Blood and urine are collected over a model-informed time course. Response (primary outcome) is defined as naltrexone-related blood oxygenation-level dependent signal change (Δ%BOLD) in a priori reward regions of interest and secondary exposure outcomes are naltrexone Cmax and AUC0-∞. Cohen's d will determine Δ%BOLD effect size, and an exposure-response model will identify target exposure to guide future dosing. This study addresses a critical knowledge gap by developing a non-invasive pharmacodynamic biomarker for youth with ED, with future applications in quantitative pharmacology, precision dosing, and the development of novel therapeutics. NCT05509257.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Feeding and Eating DisordersNaltrexoneNarcotic AntagonistsAdolescentFemaleHumansMaleYoung AdultBiomarkersBrainCross-Over StudiesDouble-Blind MethodFunctional NeuroimagingMagnetic Resonance ImagingNeuroimagingRandomized Controlled Trials as TopicReward

Stichwörter der Autor:innen

AdolescentsEating disordersNaltrexoneOpioid antagonismPharmacodynamic biomarkerfMRI

Substanzen

BiomarkersNaltrexoneNarcotic Antagonists

Autor:innen und Institutionen

  • Divisions of Adolescent Medicine and Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, United States; Department of Pediatrics, University of Missouri-Kansas City School of Medi…
  • Divisions of Adolescent Medicine and Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, United States.
  • Department of Pediatrics, University of Missouri-Kansas City School of Medicine, United States; Division of Health Services & Outcomes Research, Children's Mercy Research Institute, United States.
  • Department of Population Health, University of Kansas Medical Center, United States.
  • Department of Pediatrics, University of Missouri-Kansas City School of Medicine, United States.
  • Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, United States.

Förderung

  • NIMH NIH HHS
  • NCATS NIH HHS
  • National Institute of Mental Health
  • National Institutes of Health
  • National Center for Advancing Translational Sciences

Zitieren

APA

Stancil, S. L., Brewe, M. E., Tumberger, J., Bartkoski, M., Burns, A., Yeh, H. W., Brucks, M. G., Bartolotti, J., Voss, M., Strawn, J. R., Abdel-Rahman, S., Davis, A., Brooks, W. M., & Martin, L. E. (2025). Development of a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders: Study protocol for the naltrexone neuroimaging randomized controlled trial (NN-RCT). Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2025.107874

Vancouver

Stancil SL, Brewe ME, Tumberger J, Bartkoski M, Burns A, Yeh HW, et al. Development of a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders: Study protocol for the naltrexone neuroimaging randomized controlled trial (NN-RCT). Contemporary Clinical Trials. 2025. doi:10.1016/j.cct.2025.107874

BibTeX
@article{Stancil2025,
  author = {Stancil, Stephani L and Brewe, Mariah E and Tumberger, John and Bartkoski, Michael and Burns, Anna and Yeh, Hung-Wen and Brucks, Morgan G and Bartolotti, James and Voss, Michaela and Strawn, Jeffrey R and Abdel-Rahman, Susan and Davis, Ann and Brooks, William M and Martin, Laura E},
  title = {Development of a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders: Study protocol for the naltrexone neuroimaging randomized controlled trial (NN-RCT)},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  doi = {10.1016/j.cct.2025.107874}
}
Kostenlos starten →